MedTrace Logo

Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845

NCT00856258 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2009-12-23

No results posted yet for this study

Summary

To demonstrate the safety, pharmacokinetics and pharmacodynamics of drug candidate.

Conditions

  • Healthy Volunteers

Interventions

DRUG

PF 03882845 and Placebo

The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.

DRUG

PF 03882845 and Placebo

The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.

DRUG

PF 03882845 and Placebo

The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.

DRUG

PF 03882845 and Placebo

The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00856258 on ClinicalTrials.gov